Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 6,121 matching trials from the live ClinicalTrials.gov search.
Filters: "type 2 diabetes" Clear all
Not listed Early Phase 1 Interventional

Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy

NCT05512130
View directory record Official record
Conditions
Epilepsy
Interventions
Empagliflozin 25 mg, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Not applicable Interventional

Pilot Randomized Control Trial to Assess the Impact of Video Education on Postpartum Care Knowledge and Attendance Among Pregnant Individuals With Diabetes

NCT07009106
View directory record Official record
Conditions
Postpartum Care
Interventions
Educational video on postpartum care
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

NCT02545049
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Finerenone (BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
7,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
173
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 124 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

NCT01066715
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
XOMA 052, Placebo
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
67
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 15, 2026, 1:21 AM EDT
Completed No phase listed Observational

Cross-Sectional and Longitudinal Studies of "Pre-Diabetes" in the Pima Indians

NCT00340132
View directory record Official record
Conditions
Weight Gain, Overweight, Insulin Resistance, Obesity, Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1983
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

NCT02725593
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Dapagliflozin placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 24 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
15
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Continuous Glucose Monitoring to Measure Effect of Glycemic Index

NCT01145547
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dexcom Seven® Plus Continuous Glucose Monitoring sensor
Device
Lead sponsor
Legacy Health System
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Oct 15, 2026, 1:21 AM EDT
Recruiting Phase 3 Interventional

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes

NCT07843485
View directory record Official record
Conditions
Obesity or Overweight, Type 2 Diabetes
Interventions
Petrelintide, Placebo
Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Los Angeles, California • Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Not applicable Interventional

Project WHADE: A Partner-Based Physical Activity Program for Women

NCT06350604
View directory record Official record
Conditions
Hypertension, Type 2 Diabetes, Metabolic Syndrome, Smoking, High Cholesterol, PreDiabetes, Prehypertension
Interventions
Project WHADE: A Partner-Based Physical Activity Program for Women
Behavioral
Lead sponsor
Rowan University
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Glassboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Not applicable Interventional

Telehealth Diabetes Prevention Intervention for African American Youth

NCT04618458
View directory record Official record
Conditions
PreDiabetes, Obesity, Obesity, Childhood
Interventions
Power to Prevent
Behavioral
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
8 Years to 11 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Not applicable Interventional

Linking Self-Management and Primary Care for Diabetes 2

NCT00987285
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
CASM
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
25 Years to 75 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Not applicable Interventional Results available

Motivational Interviewing (MI) Intervention to Improve Adherence

NCT03985098
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Motivational interviewing intervention arm
Behavioral
Lead sponsor
University of Houston
Other
Eligibility
65 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 15, 2026, 1:21 AM EDT
Not listed Not applicable Interventional

Intensive Exercise to Improve Mitochondrial Dysfunction in Pediatric Obesity

NCT00962806
View directory record Official record
Conditions
Pediatric Obesity, Insulin Resistance, Mitochondrial Dysfunction
Interventions
Exercise, Lifestyle counseling
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
10 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 15, 2026, 1:21 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler

NCT01196104
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Technosphere® Insulin Inhalation Powder, Insulin Aspart, Insulin Glargine
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Mobile, Alabama • Fresno, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 15, 2026, 1:21 AM EDT
Recruiting Phase 2 Interventional

Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial

NCT06981234
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Acetazolamide, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature

NCT01248416
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
Aromatase Inhibitor, Growth Hormone, Aromatase Inhibitor and Growth Hormone
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 18 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Jacksonville, Florida • Orlando, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 15, 2026, 1:21 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

NCT03660683
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Dapagliflozin 10mg, Saxagliptin 5mg, Placebo Oral Tablet
Drug
Lead sponsor
Sabyasachi Sen
Other
Eligibility
30 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise Training and Glucose Metabolism in Aging

NCT00701051
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance (Prediabetes)
Interventions
Aerobic exercise training, Detraining (cessation of exercise)
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 15, 2026, 1:21 AM EDT
Terminated No phase listed Observational

Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management

NCT01767831
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
iBOLUSED
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

NCT06362265
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LY3209590
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Atlanta, Georgia • Columbus, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 15, 2026, 1:21 AM EDT
Recruiting Phase 2 Interventional

The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

NCT05414409
View directory record Official record
Conditions
Type 1 Diabetes, Obesity
Interventions
Metformin
Drug
Lead sponsor
Heba M. Ismail
Other
Eligibility
11 Years to 18 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects

NCT00839683
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
simvastatin, Dapagliflozin, valsartan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 15, 2026, 1:21 AM EDT
Recruiting Phase 4 Interventional

Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients

NCT06140537
View directory record Official record
Conditions
Kidney Transplant; Complications, Vascular Diseases, Diabetes
Interventions
Dapagliflozin 10mg Tab, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 15, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

A Study In Patients With Type 2 Diabetes Mellitus

NCT00256867
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK523338
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
43
States / cities
Tucson, Arizona • Fresno, California • Wheat Ridge, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 15, 2026, 1:21 AM EDT